1
|
Prevalence of seizures in brain tumor: A meta-analysis. Epilepsy Res 2022; 187:107033. [DOI: 10.1016/j.eplepsyres.2022.107033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 09/28/2022] [Accepted: 10/06/2022] [Indexed: 11/24/2022]
|
2
|
Marku M, Rasmussen BK, Belmonte F, Hansen S, Andersen EAW, Johansen C, Bidstrup PE. Prediagnosis epilepsy and survival in patients with glioma: a nationwide population-based cohort study from 2009 to 2018. J Neurol 2021; 269:861-872. [PMID: 34165627 DOI: 10.1007/s00415-021-10668-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 06/14/2021] [Accepted: 06/17/2021] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Considering that epilepsy is common, and knowledge is lacking on its role especially for the prognosis of high-grade gliomas, the objective of this study was to investigate the association between epilepsy prior to glioma diagnosis and survival among glioma patients. METHODS In a nationwide population-based cohort study, we included 3763 adult glioma patients diagnosed between 2009 and 2018 according to the Danish Neuro-Oncology Registry. Information on epilepsy was redeemed through Danish Neuro-Oncology Registry, National Patient Registry, and National Prescription Registry. Cox proportional hazard models with 95% confidence intervals (CIs) were applied to examine hazard ratios (HRs) for the association between epilepsy (< 1 year prior to glioma including epilepsy at onset; 1-10 years prior to glioma; no prior epilepsy) and risk of death, and whether it differed according to tumor grade and size, performance status, and treatment modalities. RESULTS A 32% decreased risk of death in patients with epilepsy within 1 year prior to glioma compared to no prior epilepsy was found (HR = 0.68; CI 0.63-0.75). A favorable prognosis was seen for epilepsy in all glioma grades: II (HR = 0.55; CI 0.39-0.77), III (HR = 0.59; CI 0.48-0.73), and IV (HR = 0.85; CI 0.77-0.94). CONCLUSIONS Patients with epilepsy within 1 year prior to glioma diagnosis had significant survival benefits compared to patients with no prior epilepsy. This association was significant for both low-grade gliomas (grade II) and high-grade gliomas (grade III and IV). Survival benefits in glioma patients with epilepsy at onset are possibly primarily attributable to tumor-specific histopathology, molecular biomarkers, and early diagnosis.
Collapse
Affiliation(s)
- Mirketa Marku
- Department of Neurology, North Zealand Hospital, University of Copenhagen, Hilleroed, Denmark. .,Psychological Aspects of Cancer, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark. .,Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
| | - Birthe Krogh Rasmussen
- Department of Neurology, North Zealand Hospital, University of Copenhagen, Hilleroed, Denmark
| | - Federica Belmonte
- Statistics and Data Analysis Unit, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark
| | - Steinbjørn Hansen
- Department of Oncology, Odense University Hospital, Odense, Denmark.,Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | | | - Christoffer Johansen
- Psychological Aspects of Cancer, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.,Cancer Survivorship and Treatment Late Effects (CASTLE), 9601, Department of Oncology, Centre for Cancer and Organ Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Pernille Envold Bidstrup
- Psychological Aspects of Cancer, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.,Department of Psychology, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
3
|
Bähr FS, Gess B, Müller M, Romanzetti S, Gadermayr M, Kuhl C, Nebelung S, Schulz JB, Dohrn MF. Semi-Automatic MRI Muscle Volumetry to Diagnose and Monitor Hereditary and Acquired Polyneuropathies. Brain Sci 2021; 11:brainsci11020202. [PMID: 33562055 PMCID: PMC7914808 DOI: 10.3390/brainsci11020202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2021] [Revised: 01/30/2021] [Accepted: 02/02/2021] [Indexed: 11/16/2022] Open
Abstract
With emerging treatment approaches, it is crucial to correctly diagnose and monitor hereditary and acquired polyneuropathies. This study aimed to assess the validity and accuracy of magnet resonance imaging (MRI)-based muscle volumetry.Using semi-automatic segmentations of upper- and lower leg muscles based on whole-body MRI and axial T1-weighted turbo spin-echo sequences, we compared and correlated muscle volumes, and clinical and neurophysiological parameters in demyelinating Charcot-Marie-Tooth disease (CMT) (n = 13), chronic inflammatory demyelinating polyneuropathy (CIDP) (n = 27), and other neuropathy (n = 17) patients.The muscle volumes of lower legs correlated with foot dorsiflexion strength (p < 0.0001), CMT Neuropathy Score 2 (p < 0.0001), early gait disorders (p = 0.0486), and in CIDP patients with tibial nerve conduction velocities (p = 0.0092). Lower (p = 0.0218) and upper (p = 0.0342) leg muscles were significantly larger in CIDP compared to CMT patients. At one-year follow-up (n = 15), leg muscle volumes showed no significant decrease.MRI muscle volumetry is a promising method to differentiate and characterize neuropathies in clinical practice.
Collapse
Affiliation(s)
- Friederike S. Bähr
- Department of Neurology, Medical Faculty of the RWTH Aachen University, 52074 Aachen, Germany; (F.S.B.); (B.G.); (M.M.); (S.R.); (J.B.S.)
| | - Burkhard Gess
- Department of Neurology, Medical Faculty of the RWTH Aachen University, 52074 Aachen, Germany; (F.S.B.); (B.G.); (M.M.); (S.R.); (J.B.S.)
| | - Madlaine Müller
- Department of Neurology, Medical Faculty of the RWTH Aachen University, 52074 Aachen, Germany; (F.S.B.); (B.G.); (M.M.); (S.R.); (J.B.S.)
- Department of Neurology, Inselspital Bern, CH-3010 Bern, Switzerland
| | - Sandro Romanzetti
- Department of Neurology, Medical Faculty of the RWTH Aachen University, 52074 Aachen, Germany; (F.S.B.); (B.G.); (M.M.); (S.R.); (J.B.S.)
| | - Michael Gadermayr
- Institute of Imaging and Computer Vision, RWTH Aachen University, 52074 Aachen, Germany;
- Salzburg University of Applied Sciences, 5020 Salzburg, Austria
| | - Christiane Kuhl
- Department of Diagnostic and Interventional Radiology, Medical Faculty of the RWTH Aachen University, 52074 Aachen, Germany; (C.K.); (S.N.)
| | - Sven Nebelung
- Department of Diagnostic and Interventional Radiology, Medical Faculty of the RWTH Aachen University, 52074 Aachen, Germany; (C.K.); (S.N.)
- Department of Diagnostic and Interventional Radiology, Medical Faculty, University Düsseldorf, 40225 Düsseldorf, Germany
| | - Jörg B. Schulz
- Department of Neurology, Medical Faculty of the RWTH Aachen University, 52074 Aachen, Germany; (F.S.B.); (B.G.); (M.M.); (S.R.); (J.B.S.)
- JARA-BRAIN Institute Molecular Neuroscience and Neuroimaging, ForschungszentrumJülich GmbH and RWTH Aachen University, 52425 Jülich, Germany
| | - Maike F. Dohrn
- Department of Neurology, Medical Faculty of the RWTH Aachen University, 52074 Aachen, Germany; (F.S.B.); (B.G.); (M.M.); (S.R.); (J.B.S.)
- Dr. John T. Macdonald Foundation, Department of Human Genetics and John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
- Correspondence:
| |
Collapse
|